How Safe Is that Flight? Auditors Question Airport Security

How Safe Is that Flight? Auditors Question Airport Security

REUTERS/Mario Anzuoni
By Brianna Ehley, The Fiscal Times

A government spat between Congress and the Transportation Safety Administration yesterday raised a question: Is the TSA trying to stonewall a congressional committee looking into reports suggesting the agency may be failing in its $7 billion-a-year mission to safeguard airports and air travel from terrorist threats?

At the start of Wednesday’s TSA: Are Airports Safe? hearing, House Oversight Committee Chairman Jason Chaffetz (R-UT ) immediately pointed out a glaring absence from the witness panel—the TSA.

Related: Poor Maintenance Could Make that Airport Scanner a Dud

Chaffetz said the committee had invited TSA acting administrator Melvin Carraway, but the agency offered a lower-level official in his place.

“The Department of Homeland Security objected to [Carraway’s] presence on the panel because they felt it was demeaning to have the acting director sit on the same panel as a private sector witness,” he said, referring to Raffi Fron, president of New Age Security Solutions, a company that provides security systems such as video surveillance.

The hearing was prompted by two separate but equally scathing watchdog reports that question the TSA’s ability to effectively screen passengers.

“Our audits have repeatedly found that human error— often a simple failure to follow protocol—poses significant vulnerabilities,” DHS’s IG John Roth said—adding that despite offering hundreds of recommendations the TSA has failed to assure that its mission is succeeding.

Related: Report Says TSA Wasted $1 Billion on Screening Program

DHS stood by its decision not to send its acting administrator. An agency official told The Fiscal Times that the department only participates in congressional hearing panels with other government agencies—not with private-sector witnesses in order to avoid conflicts of interest. 

A spokesperson for the committee said that “witness invitations are not transferable” and that the “DHS does not dictate how we run our hearings.”

This isn’t the only roadblock the Oversight Committee has run into with the TSA. During the hearing, Chairman Chaffetz showed off a heavily redacted document he had requested from the agency—saying even members of Congress had “exceptional” difficulties getting information from them.

The committee spokesperson said House Oversight is currently looking into other ways the TSA has frustrated congressional inquiries—and what kinds of action can be taken.

Tax Refunds Rebound

Flickr / Chris Potter
By The Fiscal Times Staff

Smaller refunds in the first few weeks of the current tax season were shaping up to be a political problem for Republicans, but new data from the IRS shows that the value of refund checks has snapped back and is now running 1.3 percent higher than last year. The average refund through February 23 last year was $3,103, while the average refund through February 22 of 2019 was $3,143 – a difference of $40. The chart below from J.P. Morgan shows how refunds performed over the last 3 years. 

Number of the Day: $22 Trillion

iStockphoto/The Fiscal Times
By The Fiscal Times Staff

The total national debt surpassed $22 trillion on Monday. Total public debt outstanding reached $22,012,840,891,685.32, to be exact. That figure is up by more than $1.3 trillion over the past 12 months and by more than $2 trillion since President Trump took office.

Chart of the Week: The Soaring Cost of Insulin

Client Sanon has her finger pricked for a blood sugar test in the Family Van in Boston
REUTERS/Brian Snyder
By The Fiscal Times Staff

The cost of insulin used to treat Type 1 diabetes nearly doubled between 2012 and 2016, according to an analysis released this week by the Health Care Cost Institute. Researchers found that the average point-of-sale price increased “from $7.80 a day in 2012 to $15 a day in 2016 for someone using an average amount of insulin (60 units per day).” Annual spending per person on insulin rose from $2,864 to $5,705 over the five-year period. And by 2016, insulin costs accounted for nearly a third of all heath care spending for those with Type 1 diabetes (see the chart below), which rose from $12,467 in 2012 to $18,494. 

Chart of the Day: Shutdown Hits Like a Hurricane

An aerial view shows a neighborhood that was flooded after Hurricane Matthew in Lumberton, North Carolina
© CHRIS KEANE / Reuters
By Michael Rainey

The partial government shutdown has hit the economy like a hurricane – and not just metaphorically. Analysts at the Committee for a Responsible Federal Budget said Tuesday that the shutdown has now cost the economy about $26 billion, close to the average cost of $27 billion per hurricane calculated by the Congressional Budget Office for storms striking the U.S. between 2000 and 2015. From an economic point of view, it’s basically “a self-imposed natural disaster,” CRFB said. 

Chart of the Week: Lowering Medicare Drug Prices

A growing number of patients are being denied access to newer oral chemotherapy drugs for cancer pills with annual price tags of more than $75,000.
iStockphoto
By Michael Rainey

The U.S. could save billions of dollars a year if Medicare were empowered to negotiate drug prices directly with pharmaceutical companies, according to a paper published by JAMA Internal Medicine earlier this week. Researchers compared the prices of the top 50 oral drugs in Medicare Part D to the prices for the same drugs at the Department of Veterans Affairs, which negotiates its own prices and uses a national formulary. They found that Medicare’s total spending was much higher than it would have been with VA pricing.

In 2016, for example, Medicare Part D spent $32.5 billion on the top 50 drugs but would have spent $18 billion if VA prices were in effect – or roughly 45 percent less. And the savings would likely be larger still, Axios’s Bob Herman said, since the study did not consider high-cost injectable drugs such as insulin.